Reducing Risk of Stroke and DementIa in PatientS with COVert CERebrovascular Disease
Launched by UNIVERSITY OF EDINBURGH · Mar 13, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
DISCOVER is a prospective cohort involving individuals with covert cerebrovascular disease (CCD) in NHS Lothian. Participants will be recruited through electronic health records and clinician collaborators. Participants will be monitored at 3 and 6 months and where possible 12 months to assess cognitive, functional, and vascular event outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • People who, at the time the letter is prepared or are identified by a clinician
- • Age ≥ 65 years
- * Have no known history of:
- • Stroke or TIA
- • Dementia
- • Parkinson's disease
- • Multiple sclerosis
- • Metastatic cancer (or non-meningioma brain tumour).
- * A CT or MRI scan report ≤5 years before study start date with of one or more of:
- • Cerebral small vessel disease
- • Deep old ischaemic stroke
- • Cortical old ischaemic stroke
- Exclusion Criteria:
- • Text of brain scan report unreadable
- • Do not consent to take part in study procedures
- • Unable to consent
- • Unable to communicate by email, letter or telephone through language, speech disability or lack of address
- • Unlikely to survive one year past enrolment in judgement of the study investigator
About University Of Edinburgh
The University of Edinburgh, a prestigious institution renowned for its commitment to research excellence and innovation, serves as a leading clinical trial sponsor dedicated to advancing healthcare through rigorous scientific inquiry. With a strong emphasis on multidisciplinary collaboration, the university facilitates cutting-edge clinical studies that aim to explore novel therapies and improve patient outcomes. Leveraging its extensive network of researchers, healthcare professionals, and state-of-the-art facilities, the University of Edinburgh is at the forefront of translating scientific discoveries into practical applications, thereby contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported